

Addendum

Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial**Guillermo de Velasco¹, Lucia Carril-Ajuria¹, Felix Guerrero-Ramos², Teresa Alonso-Gordo³, Juan F. Rodríguez-Moreno⁴, Alberto Carretero¹, Maricruz Martín-Soberón¹, Federico de la Rosa-Kehrmann² and Daniel Castellano¹**¹Medical Oncology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain²Urology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain³Medical Oncology Department, Hospital Universitario Ramón y Cajal, Comunidad de Madrid, Madrid, Spain⁴Medical Oncology Department, Hospital Universitario HM Sanchinarro, Comunidad de Madrid, Madrid, Spain**Published:** August 04, 2022**Copyright:** © 2022 de Velasco et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**Consent was added to this article:** All patients signed informed consent.Original article: Oncotarget. 2020; 11:4457–4462. <https://doi.org/10.18632/oncotarget.27807>